Evolus, Inc. (LON:0K16)

Market Cap	204.28M -71.8%
Revenue (ttm)	212.64M +15.1%
Net Income	-43.57M
EPS	-0.68
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52
Average Volume	3,893
Open	14.31
Previous Close	14.16
Day's Range	14.31 - 14.58
52-Week Range	9.31 - 17.81
Beta	n/a
RSI	65.90
Earnings Date	Mar 6, 2026

About Evolus

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 329
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K16

Financial Performance

In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.

Financial numbers in USD